Why the study?
The review aimed to provide an overview of the safety and efficacy of available treatments for spinal muscular atrophy, incorporating evidence from clinical trials, real-world data, and ongoing studies using approaches other than increasing SMN protein.
Answers are grounded in this paper and cite their sources.
Real-world data from over 24 recent studies support the safety and efficacy of available SMA treatments across diverse patient profiles.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pera et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: